Bevacizumab for the treatment of pediatric retinal and choroidal diseases

Robert A. Sisk, Audina Berrocal, Thomas A Albini, Timothy G. Murray

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

■ BACKGROUND AND OBJECTIVE: To determine the efficacy of off-label intravitreal bevacizumab (IVB) for the treatment of pediatric retinal and choroidal vascular diseases. ■ PATIENTS AND METHODS: Retrospective, noncomparative, open-label, interventional, consecutive case series of all patients younger than 18 years treated with off-label IVB at a single center from January 1, 2005, to January 1, 2008. Primary outcome measures with best-corrected visual acuity by age-appropriate testing and central macular thickness by time-domain optical coherence tomography. ■ RESULTS: Thirty-five eyes of 33 patients were treated with IVB alone or in combination with other treatments for choroidal neovascularization, Coats' disease, familial exudative vitreoretinopathy, and various other indications.IVB was used in 24 eyes to reduce excess retinal fluid and exudation. Mean Snellen visual acuity improved from 20/170 at baseline to 20/100 at 1 month (P = .006), 20/80 at 3 months (P = .006), and 20/50 at 6 months (P = .023). Central macular thickness improved from 356 μm at baseline to 287 μm at 6 months (P = .028). IVB was used in 11 eyes to control peripheral retinal neovascularizationand iris rubeosis. Although IVB reduced vascular engorgement, it did not prevent the progression of preretinal tractional forces. Mean visual acuity was maintained at each time point. No systemic or ocular adverse events were directly attributable to IVB in any patient. ■ CONCLUSION: IVB reduced vascular leakage and temporarily regressed pathologic neovascularization of the choroid, retina, and iris in this series of pediatric patients. Further prospective studies are warranted.

Original languageEnglish
Pages (from-to)582-592
Number of pages11
JournalOphthalmic Surgery Lasers and Imaging
Volume41
Issue number6
DOIs
StatePublished - Nov 1 2010

Fingerprint

Choroid Diseases
Retinal Diseases
Pediatrics
Visual Acuity
Iris
Therapeutics
Blood Vessels
Retinal Telangiectasis
Pathologic Neovascularization
Retinal Vessels
Choroidal Neovascularization
Choroid
Bevacizumab
Optical Coherence Tomography
Vascular Diseases
Retina
Outcome Assessment (Health Care)
Prospective Studies

ASJC Scopus subject areas

  • Ophthalmology
  • Surgery
  • Medicine(all)

Cite this

Bevacizumab for the treatment of pediatric retinal and choroidal diseases. / Sisk, Robert A.; Berrocal, Audina; Albini, Thomas A; Murray, Timothy G.

In: Ophthalmic Surgery Lasers and Imaging, Vol. 41, No. 6, 01.11.2010, p. 582-592.

Research output: Contribution to journalArticle

@article{1b0e96a4689b463ba8210766274196cf,
title = "Bevacizumab for the treatment of pediatric retinal and choroidal diseases",
abstract = "■ BACKGROUND AND OBJECTIVE: To determine the efficacy of off-label intravitreal bevacizumab (IVB) for the treatment of pediatric retinal and choroidal vascular diseases. ■ PATIENTS AND METHODS: Retrospective, noncomparative, open-label, interventional, consecutive case series of all patients younger than 18 years treated with off-label IVB at a single center from January 1, 2005, to January 1, 2008. Primary outcome measures with best-corrected visual acuity by age-appropriate testing and central macular thickness by time-domain optical coherence tomography. ■ RESULTS: Thirty-five eyes of 33 patients were treated with IVB alone or in combination with other treatments for choroidal neovascularization, Coats' disease, familial exudative vitreoretinopathy, and various other indications.IVB was used in 24 eyes to reduce excess retinal fluid and exudation. Mean Snellen visual acuity improved from 20/170 at baseline to 20/100 at 1 month (P = .006), 20/80 at 3 months (P = .006), and 20/50 at 6 months (P = .023). Central macular thickness improved from 356 μm at baseline to 287 μm at 6 months (P = .028). IVB was used in 11 eyes to control peripheral retinal neovascularizationand iris rubeosis. Although IVB reduced vascular engorgement, it did not prevent the progression of preretinal tractional forces. Mean visual acuity was maintained at each time point. No systemic or ocular adverse events were directly attributable to IVB in any patient. ■ CONCLUSION: IVB reduced vascular leakage and temporarily regressed pathologic neovascularization of the choroid, retina, and iris in this series of pediatric patients. Further prospective studies are warranted.",
author = "Sisk, {Robert A.} and Audina Berrocal and Albini, {Thomas A} and Murray, {Timothy G.}",
year = "2010",
month = "11",
day = "1",
doi = "10.3928/15428877-20100830-03",
language = "English",
volume = "41",
pages = "582--592",
journal = "Ophthalmic Surgery Lasers and Imaging Retina",
issn = "2325-8160",
publisher = "Slack Incorporated",
number = "6",

}

TY - JOUR

T1 - Bevacizumab for the treatment of pediatric retinal and choroidal diseases

AU - Sisk, Robert A.

AU - Berrocal, Audina

AU - Albini, Thomas A

AU - Murray, Timothy G.

PY - 2010/11/1

Y1 - 2010/11/1

N2 - ■ BACKGROUND AND OBJECTIVE: To determine the efficacy of off-label intravitreal bevacizumab (IVB) for the treatment of pediatric retinal and choroidal vascular diseases. ■ PATIENTS AND METHODS: Retrospective, noncomparative, open-label, interventional, consecutive case series of all patients younger than 18 years treated with off-label IVB at a single center from January 1, 2005, to January 1, 2008. Primary outcome measures with best-corrected visual acuity by age-appropriate testing and central macular thickness by time-domain optical coherence tomography. ■ RESULTS: Thirty-five eyes of 33 patients were treated with IVB alone or in combination with other treatments for choroidal neovascularization, Coats' disease, familial exudative vitreoretinopathy, and various other indications.IVB was used in 24 eyes to reduce excess retinal fluid and exudation. Mean Snellen visual acuity improved from 20/170 at baseline to 20/100 at 1 month (P = .006), 20/80 at 3 months (P = .006), and 20/50 at 6 months (P = .023). Central macular thickness improved from 356 μm at baseline to 287 μm at 6 months (P = .028). IVB was used in 11 eyes to control peripheral retinal neovascularizationand iris rubeosis. Although IVB reduced vascular engorgement, it did not prevent the progression of preretinal tractional forces. Mean visual acuity was maintained at each time point. No systemic or ocular adverse events were directly attributable to IVB in any patient. ■ CONCLUSION: IVB reduced vascular leakage and temporarily regressed pathologic neovascularization of the choroid, retina, and iris in this series of pediatric patients. Further prospective studies are warranted.

AB - ■ BACKGROUND AND OBJECTIVE: To determine the efficacy of off-label intravitreal bevacizumab (IVB) for the treatment of pediatric retinal and choroidal vascular diseases. ■ PATIENTS AND METHODS: Retrospective, noncomparative, open-label, interventional, consecutive case series of all patients younger than 18 years treated with off-label IVB at a single center from January 1, 2005, to January 1, 2008. Primary outcome measures with best-corrected visual acuity by age-appropriate testing and central macular thickness by time-domain optical coherence tomography. ■ RESULTS: Thirty-five eyes of 33 patients were treated with IVB alone or in combination with other treatments for choroidal neovascularization, Coats' disease, familial exudative vitreoretinopathy, and various other indications.IVB was used in 24 eyes to reduce excess retinal fluid and exudation. Mean Snellen visual acuity improved from 20/170 at baseline to 20/100 at 1 month (P = .006), 20/80 at 3 months (P = .006), and 20/50 at 6 months (P = .023). Central macular thickness improved from 356 μm at baseline to 287 μm at 6 months (P = .028). IVB was used in 11 eyes to control peripheral retinal neovascularizationand iris rubeosis. Although IVB reduced vascular engorgement, it did not prevent the progression of preretinal tractional forces. Mean visual acuity was maintained at each time point. No systemic or ocular adverse events were directly attributable to IVB in any patient. ■ CONCLUSION: IVB reduced vascular leakage and temporarily regressed pathologic neovascularization of the choroid, retina, and iris in this series of pediatric patients. Further prospective studies are warranted.

UR - http://www.scopus.com/inward/record.url?scp=79953246911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953246911&partnerID=8YFLogxK

U2 - 10.3928/15428877-20100830-03

DO - 10.3928/15428877-20100830-03

M3 - Article

C2 - 20839668

AN - SCOPUS:79953246911

VL - 41

SP - 582

EP - 592

JO - Ophthalmic Surgery Lasers and Imaging Retina

JF - Ophthalmic Surgery Lasers and Imaging Retina

SN - 2325-8160

IS - 6

ER -